Roche: Phase III Study Of Tecentriq Combination In Hepatocel

SOUTH SAN FRANCISCO (dpa-AFX) - Pivotal Phase III IMbrave050 study, which investigated Tecentriq plus Avastin in people with early-stage hepatocellular carcinoma or HCC at high risk of recurrence

Related Keywords

, Genentech , European Medicines Agency , Drug Administration , Roche Group , More Such Health News , Roche , Hase , Study , Tecentriq , Combination , Hepatocellular , Arcinoma , Meets , Primary , Ndpoint ,